BCRX Insider Trading
Insider Ownership Percentage: 4.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
BioCryst Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at BioCryst Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
BioCryst Pharmaceuticals Share Price & Price History
Current Price: $8.61
Price Change: ▼ Price Decrease of -0.09 (-1.03%)
As of 07/18/2025 05:00 PM ET
BioCryst Pharmaceuticals Insider Trading History
BioCryst Pharmaceuticals Institutional Trading History
Data available starting January 2016
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More on BioCryst Pharmaceuticals
Volume
3,104,683 shs
Average Volume
3,039,523 shs
Market Capitalization
$1.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.04
Who are the company insiders with the largest holdings of BioCryst Pharmaceuticals?
Who are the major institutional investors of BioCryst Pharmaceuticals?
Which major investors are selling BioCryst Pharmaceuticals stock?
During the last quarter, BCRX stock was sold by these institutional investors:
- Moody National Bank Trust Division
- Janney Montgomery Scott LLC
- Pallas Capital Advisors LLC
Which major investors are buying BioCryst Pharmaceuticals stock?
In the last quarter, BCRX stock was acquired by institutional investors including:
- Assenagon Asset Management S.A.
- Doliver Advisors LP
- Family Legacy Financial Solutions LLC
Within the previous year, these company insiders have bought BioCryst Pharmaceuticals stock:
- Helen M Thackray (Insider)
- Anthony Doyle (CFO)
- Nancy J Hutson (Director)
- Steven K Galson (Director)
- Alan G Levin (Director)
- Amy E Mckee (Director)
Learn More investors buying BioCryst Pharmaceuticals stock.